ANORO ELLIPTA (umeclidinium bromide)
Anoro Ellipta is a combination inhaler used for the long-term maintenance of patients with chronic obstructive pulmonary disease (COPD). It helps patients manage their condition by providing ongoing support to keep the airways open and improve airflow. This medication is not intended to provide quick relief for sudden breathing difficulties or to manage asthma.
How ANORO ELLIPTA Works
This medication works by combining two different types of bronchodilators that target the muscles in the airways. Umeclidinium blocks specific muscarinic receptors to prevent muscle contraction, while vilanterol stimulates enzymes that help relax the airway smooth muscle. Together, these actions help open the airways and improve breathing.
Details
- Status
- Prescription
- First Approved
- 2013-12-18
- Patent Cliff
- 2030
- Routes
- INHALATION
- Dosage Forms
- POWDER
ANORO ELLIPTA Approval History
What ANORO ELLIPTA Treats
1 indicationsANORO ELLIPTA is approved for 1 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Chronic Obstructive Pulmonary Disease
ANORO ELLIPTA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ANORO ELLIPTA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03002389 | 19569-19352 | Ph 2 | active not recruiting | Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics |
| NCT02184611 results posted | 117410 | Ph 3 | completed | A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI) |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ANORO ELLIPTA FDA Label Details
Indications & Usage
FDA Label (PDF)ANORO ELLIPTA is indicated for the treatment of Chronic Obstructive Pulmonary Disease.
ANORO ELLIPTA Patents & Exclusivity
Patents (6 active)
Pro Intelligence Preview
Deep insights for ANORO ELLIPTA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2030
- • 6 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.